

NEWS RELEASE

December 21, 2011

Trading Symbol: TSX-V: APC

ADVANCED PROTEOME APPOINTS NEW DIRECTOR

Advanced Proteome Therapeutics Corporation (the “Company” or “APC”) is pleased to announce that its Board of Directors has elected Edward K. (Kelly) Hyslop, MD, to the Board as a Director, effective December 19, 2011. Dr. Hyslop is a graduate of Dalhousie University, where he received the MD degree. He retired after 25 years after serving in General Practice and as a Clinical Professor in the Department of Medicine at the University of British Columbia. Kelly has been involved in multiple start-up Resource Projects, Earth Science and Biotechnology companies, generally raising capital, advising strategy at the inter-phase between science and finance, and active on the Board of Directors of such companies, in driving their evolution from a technology concept start-up to a commercial enterprise.

“I am delighted to welcome Kelly to the Board of Directors of APC,” said Dr. Alexander Krantz, CEO and President. “His deep understanding and commitment to fostering growth of early stage companies is extremely relevant to APC’s business, and his guidance will be invaluable as we develop and execute our strategic plan toward driving the adoption of APC products and technology throughout the industry”.

About APC

APC’s primary corporate mission is to advance chemical methods which afford advantages to site-specifically modify proteins to impact critical unmet medical needs. Site-specific modifications represent the gold standard underlying redevelopment technologies to produce new, improved versions of therapeutic proteins and the ultimate regulatory standard for the production of new protein therapeutics. APC is applying its chemical platform “Swift Linkage Multivalent Technology” to specifically target cells which reveal phosphatidylserine, a distinctive feature in multiple diseases with elevated sites of apoptosis and necrosis as well as certain cancers. The combination of the chemical platform focusing on site specific modifications of protein products and their site-specific delivery to cellular targets has broad therapeutic potential.

ON BEHALF OF THE BOARD

Alexander (Allen) Krantz
President and Chief Executive Officer

FOR FURTHER INFORMATION PLEASE CONTACT:

Advanced Proteome Therapeutics Inc.
Tel: (800) APT 1169

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.